Avalon GloboCare Corp. 8-K

What Happened

• Avalon GloboCare Corp. (ALBT) filed an 8‑K reporting that at a special stockholders meeting on March 30, 2026, shareholders approved seven proposals including approvals required under Nasdaq rules for multiple share issuances, an equity exchange with the chairman, the grant of restricted shares to an advisor, and board authority to effect a reverse stock split between 1‑for‑2 and 1‑for‑25. A quorum of 2,498,866 shares was represented in person or by proxy.

Key Details

• Stockholder approvals included: conversion issuances for July 2025 Convertible Notes and a December 11, 2025 bridge note (including 100,000 “Commitment Shares”), and conversion of Series C convertible preferred stock.
• The board-approved Exchange Agreement (Feb 18, 2026) to exchange 5,000 shares of Series D preferred held by Chairman Wenzhao Lu for 2,074,689 common shares was approved by shareholders.
• Share issuance approvals also covered 450,000 restricted common shares to an advisor under a consulting agreement (dated Dec 1, 2025, amended Feb 16, 2026).
• Shareholders authorized the board to effect, at its discretion and without further stockholder approval, a reverse stock split at a ratio between 1‑for‑2 and 1‑for‑25, to be implemented if the board chooses before March 30, 2028. Vote tallies: Reverse split — For 2,325,637; Against 141,069; Abstain 32,160. Earlier conversion/issuance proposals showed ~1,006,000 For and 1,482,604 broker non‑votes.

Why It Matters

• These approvals will allow the company to issue shares when convertible instruments convert and to complete a significant share exchange with the chairman, which will increase the company’s outstanding common shares and may dilute existing holders when conversions or exchanges occur.
• The reverse stock split authorization gives the board flexibility to reduce the number of outstanding shares (between 1‑for‑2 and 1‑for‑25) without another shareholder vote; such a split can affect per‑share price, liquidity and share float but will not change overall company value. Approval also satisfies Nasdaq vote/issuance requirements, which can be relevant to the company’s listing status.